The company filed a lawsuit to stop a federal decision that could be very bad news for its top drug.
Aurora Cannabis, Cronos Group, and Tilray Earnings Results Are In: Here's What They Could Mean for Canopy Growth
Based on its peers' results, Canopy Growth could be in for a pretty good quarter.
Unanswered questions for the marijuana producer could keep the stock from flying as high as it could.
Two rising biotech stocks. One clear long-term winner.
They're leaders in their markets. And those markets should grow tremendously.
Can these high-flying biotech stocks keep the momentum going?
These two biotechs could have a tortoise-and-hare kind of race going on.
Which stock wins in a matchup between these two big drugmakers?
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Which stock wins in a head-to-head matchup between these two clinical-stage biotechs?
One of these marijuana stocks has been the bigger winner recently. But which is better poised to win in the future?
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
But there are also two reasons that it might not.
Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate.
Sure, Aurora's Q3 revenue growth was fantastic. But here's what the company reported that points to an even brighter future.
The Canadian cannabis producer delivered skyrocketing revenue growth but a widening net loss in the third quarter.
The Canadian cannabis producer appears to be set to make its mark in the potentially lucrative U.S. hemp market.
These look like great picks to buy in May before you go away.
The Canadian marijuana producer's revenue nearly tripled year over year in Q1. Here's why.
An analyst upgrade fueled optimism for the beaten-down stock.